Atossa presents preclinical data on (Z)-endoxifen for muscular dystrophy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Nasdaq ends lower with tech; investors assess softer jobs data
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
March 12, 2026 8:01 AM EDTStudy Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice
SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in... More
